Small-Molecule APIs

Efficiency Demands Drive Advances in API Labs

October 02, 2018

Integration of new modeling and analytical tools with flow chemistry are notable trends.

Cambrex Completes Acquisition of Halo Pharma

September 18, 2018

The $425-million acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

FDA Expands NDMA Investigation to All ARB Class Drugs

September 04, 2018

As it investigates the root cause of an impurity discovered in valsartan, FDA extends its studies to APIs with similar synthesis processes.

Can Artificial Intelligence Take the Next Step for Drug Repositioning?

September 02, 2018

Existing software tools cannot take into account the complexity of disease.

Increasing API Complexity Drives Demand for Cryogenic Capabilities

August 02, 2018

Low-temperature chemistry enables performance of more challenging and selective chemistry.

Cambrex to Acquire Halo Pharma for $425 Million

July 23, 2018

The acquisition will place Cambrex into the finished dosage form CDMO market.

New Tools Outline Advances for Continuous API Processing

June 02, 2018

From separation systems to reactor technology, new tools are increasing the feasibility of continuous API production.

Cambrex Reports Expansions at its High Point, NC Facility

May 16, 2018

Cambrex Corporation has announced facility, equipment, and instrument upgrades at its High Point, NC facility and updated progress on expansions in Cedar City, IA.

Porton Pharma Solutions and Codexis Partner on Biocatalysts

April 24, 2018

Porton will use biocatalyst technologies from Codexis to accelerate API development for clients.

AMRI Wins NIH Contract Renewal for Neurotherapeutics

April 20, 2018

The contract renewal allows AMRI to continue to provide medicinal chemistry and ADME services for advancing drug discovery programs in neurotherapeutics.